Bright Business Consulting LLP

Monday, July 16, 2018

Life Science and Biotechnologies in United Kingdom (UK)

The field of "Life Sciences and Biotechnology in United Kingdom - (UK)" is a European reference, in particular in the fields of pharmaceutical, diagnostics, chemical and Agrifood industry . There are over 430 biotechnology companies as well as service providers with a turnover of approximately 2.5 billion GBP. The majority of companies are small / medium sized. However, there are major companies including Acambis, Shire, and Celltech Cobra accounting for about 70% of the continental market capitalization of Biotech sector.

The key areas of Life Sciences can be distinguished in:

  • Neuroscience.
  • Oncology.
  • Manufacture.
  • Bioprocessing.
  • Tissue Engineering and Regenerative Medicine.
  • Clinical Research.
  • Marine Biotechnology.
  • Biotechnology of Agribusiness.
  • Nutraceuticals.
  • Medical Imaging.
  • Bio-nanotechnology.
  • Industrial Biotechnology.


The UK is one of the favorite destinations for international operations in the pharmaceutical/biotech field, being the second exporter in the world of pharmaceutical products. The ten largest international pharmaceutical firms
have a significant presence, and in some cases, a strong manufacturing base, research and development in the UK. The pharmaceutical industry involves about 73 000 employees, whose one-third works in research and over 22 thousand are emplyed in Biotechnology.

The UK is the fifth largest pharmaceutical market in the world in terms of turnover and the NHS (National Health Service) is one of the largest purchasers of drugs. Among the current top 100 drugs in the worldwide market, 18 of them have been discovered and produced in the UK. The pharmaceutical sector is also responsible for financing more than 25% of the investment involving manufacturing industry's research. The primary role of British pharmaceutical manufacturing is helped by huge international investments by large companies (such as Novartis, Grimsby, Abbott). The pharmaceutical industry invests more than 8 billion GBP in clinical trial in the UK with hundreds of new drugs tested each year.

Clinical trial is a very risky and unpredictable. Medications sometimes do not overcome the tests and unforeseen circumstances may adversely affect their marketing. In addiction, pharmaceutical industry is the most regulated of all fields in the market, with regulations that vary from Country to Country and often from year to year. In the nineties, there has been a phenomenon of transformation of the pharmaceutical industry.

The industry that first made use only of its companies, has begun to address CROS (External Organizations Research on Contract) to supply the growing demand and to accelerate the clinical trial. This approach has also facilitated the opening to foreign markets. The British Government has shown a commitment to supporting the industry by creating incentives and Tax Credits with a program of increased public spending for Science and Biotechnology by 10%.

The UK is also asserting its supremacy with regard to bioprocessing activities. Bioprocessing includes all processes that can turn bio-drugs from its experimental stage into a marketable product. To maintain the leading position in the industry, the Government and the British industry subsidize and invest in laboratories and centers of excellence.

The UK plays a major role in Biotechnology, thanks to a now consolidated knowledge in traditional Chemical, Agri-food, Marine fields and a new type of approach aimed at integrating the various branches of Biotechnology, which are named White, Green and Blue. Companies focus on Universities and Centers of Excellence, whose most important one is in Cambridge. Other major research centers are set in Edinburgh, London, Glasgow, Liverpool and Manchester, Newcastle and Oxford. The strength of Biotechnology is its interaction among research, Industry and professional and institutional investors. British Biotechnology Institutions are increasingly opening up to international collaboration, in particular with research centers which are located in developing Countries.


Pharmaceutical Industry is constantly looking for new molecules that can turn into drugs and care products of the future. This activity of bioprocessing has focused its attention on the vast potential of raw materials, biotech products and processes represented by the marine environment.

The UK owns 50 institutes of bio-marine biotechnology of great experience and a number of specialized University departments, with a tradition of industrial collaboration and entrepreneurial activity. A lot of of well-established drugs on the market are made of natural products and their market value is around $ 22 billion. Given this economic potential, the Pharmaceutical sector is the main target for marine bioprocessing.


The cloning of Dolly, the creation of the sequence of the genome of Arabidopsis, a number of revolutionary scientific discoveries and innovations have characterized this field which is so-called "AgBio", agri-food biotechnology. These discoveries have opened new chances not only for the improvement of crops and livestock, but also for the technologies towards the environment such as bioremediation and biofuels. Furthermore, significant advantages have been obtained in medical research and in the applications of tissue regeneration.

The success of agri-food biotechnology explains why the largest multinational companies, including Bayer Crio Science, Syngenta, Dow AgroSciences, DuPont, Monsanto and BASF all have a significant presence in the United Kingdom. All major British research centers have a commercial branch to encourage interaction with the industry and investment in the community. In this way, the new discoveries are more easily convertible into new products and / or marketable technologies.

The United Kingdom has undertaken a campaign to promote agri-food biotechnology in order to raise public awareness to the advantages and benefits that this technology can bring to agriculture, the environment and the human community. The ethical use of genetic technologies, in particular, helps to reduce both animal and human illnesses, benefiting from the food production and the ecological system.

Given that Bright Business Consulting LLP does not work in the field of "Life Sciences and Biotechnology" in the first person, but it is rather involved in this sector through consolidated and calcified synergies in the "PEE Project ", useful to the accompaniment of the companies interested in this market. However, in this scenario the analysis through a "Counselling Aimed at Company Investigations & Commercial Information " is a right suggestion, especially for those businesses that want to operate in the field of "Life Sciences and Biotechnology in United Kingdom – (UK)".


In order to operate successfully, today and in perspective, in the growing field of "Information and Communication Technologies in United Kingdom – (UK)" is absolutely advisable to have a local strong commercial presence also with the aim of accessing both contributions and "Tax Incentives in United Kingdom – (UK)". For such a purpose a British corporate body with suitable accreditations is advisable, so Bright Business Consulting LLP is the ideal partner for the fulfilment of what has been already mentioned.



Bright Business Consulting LLP
58/60 - Kensington Church Street


fb  linkedin  twitter  


Scroll to Top